GBLX Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume3.80K
Average Volume (3M)N/A
Market Cap
$122.12K
Enterprise Value$1.87M
Total Cash (Recent Filing)$3.02K
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta-174.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding407,071,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.49
Price to Sales (P/S)0.00
P/FCF Ratio-2.64
Enterprise Value/Market Cap15.31
Enterprise Value/Revenue19.23
Enterprise Value/Gross Profit19.23
Enterprise Value/Ebitda-2.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GB Sciences News
GBLX FAQ
What was GB Sciences Inc’s price range in the past 12 months?
Currently, no data Available
What is GB Sciences Inc’s market cap?
GB Sciences Inc’s market cap is $122.12K.
When is GB Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GB Sciences Inc’s earnings last quarter?
GB Sciences Inc released its earnings results on Feb 15, 2018. The company reported -$0.05 earnings per share for the quarter.
Is GB Sciences Inc overvalued?
According to Wall Street analysts GB Sciences Inc’s price is currently Overvalued.
Does GB Sciences Inc pay dividends?
GB Sciences Inc does not currently pay dividends.
What is GB Sciences Inc’s EPS estimate?
GB Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GB Sciences Inc have?
GB Sciences Inc has 407,071,000 shares outstanding.
What happened to GB Sciences Inc’s price movement after its last earnings report?
GB Sciences Inc reported an EPS of -$0.05 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of GB Sciences Inc?
Currently, no hedge funds are holding shares in GBLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GB Sciences Inc
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
Ownership Overview
―
Insiders
―
Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors